3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
25
Neoplasms
12
Prostatic Neoplasms
9
Multiple Myeloma
9
Neoplasm Metastasis
7
Giant Cell Tumor of Bone
7
Osteoporosis
4
Fractures, Bone
4
Recurrence
3
Kidney Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Bone Diseases, Metabolic
3
Bone Diseases
3
Spinal Cord Compression
2
Smoldering Multiple Myeloma
2
Parathyroid Neoplasms
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Bone Neoplasms
2
Bone Metastases
2
Bone Cysts, Aneurysmal
2
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer Metastatic
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Interventions
Cyclophosphamide
38
Paclitaxel
22
Epirubicin
21
Trastuzumab
20
Docetaxel
20
Doxorubicin
19
Carboplatin
15
Radiotherapy
13
Taxes
11
Filgrastim
11
Neoadjuvant Therapy
9
Bevacizumab
9
Fluorouracil
8
pembrolizumab
7
Tamoxifen
7
Albumin-Bound Paclitaxel
7
Capecitabine
6
pertuzumab
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Lapatinib
5
130-nm albumin-bound paclitaxel
5
pegfilgrastim
4
Granulocyte Colony-Stimulating Factor
4
Cisplatin
4
Chemotherapy, Adjuvant
4
tipifarnib
3
eribulin
3
Surgical Procedures, Operative
3
Specimen Handling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Inflammatory Breast Neoplasms
×
Denosumab
×
Clear all
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled